Gilead Sciences : View Second Quarter 2021 Earnings Slides

Q221 Financial Results

J u l y 2 9 , 2 0 2 1

Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the development, manufacturing and distribution of Veklury (remdesivir) as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales, Gilead's ability to recoup the expenses incurred to date and future expenses related to the development and production of Veklury, and Gilead's ability to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2021 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead's ability to make progress on any of its long- term ambitions or strategic priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its antiviral and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all; the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Hepcludex (bulevirtide), Trodelvy and Yescarta; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including lenacapavir and magrolimab, or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates in the currently anticipated timelines, including those involving Hepcludex, Yescarta, lenacapavir and magrolimab; Gilead's ability to receive regulatory approvals in a timely manner or at all, including FDA approval of Tecartus for treatment of acute lymphoblastic leukemia and EMA approval of Trodelvy for treatment of metastatic triple- negative breast cancer, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June 30, 2021 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The reader is cautioned that forward- looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation and disclaims any intent to update such forward-looking statements. All forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

This presentation includes U.S. GAAP and non-GAAP financial measures, a complete reconciliation between these two measures is available on the Company's website at www.gilead.com within the investor section. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX® (BULEVIRTIDE), HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. This presentation also includes trademarks, service marks and trade names of other companies.

COVID-19

Insight

Statements

We have provided these insights based on management's current expectations, estimates and judgments, which are based on information available as of the date of this presentation and certain assumptions that it believes to be reasonable under the circumstances, but the risks and uncertainties related to the COVID-19 pandemic and related public health measures could cause actual results to differ materially. The extent to which the COVID-19 pandemic impacts our business, financial condition and results of operations will depend on future developments, which are uncertain and cannot be predicted with confidence, including the duration and scope of the outbreak, any potential future waves of the pandemic, new information which may emerge concerning the severity of COVID-19 and the ongoing or future actions to contain it or treat its impact, among others. The ongoing COVID-19 pandemic may also affect our operating and financial results in a manner that is not presently known to us or that we currently do not consider to present significantrisks to our operations.

2

Contents

Q221 Highlights

Commercial Highlights

CMO Updates

Financial Performance

Appendix

4-5

6-13

14-19

20-23

25-31

3

Gilead Q221 Key Takeaways

Solid Q221 & 1H21 Financial Results

Strong 1H21 Pipeline Execution

Delivering on Strategic Initiatives

• Q221 total product sales increased 21% YoY; products sales ex-Veklury increased 5% YoY
• Biktarvy grew $390M, or 24% YoY, offsetting $322M lower Truvada/Atripla sales
• Pace of pandemic recovery continues to impact the US HIV treatment market
• Delivered on all key YTD milestone targets, including 4 in Q221
• Shared exciting ZUMA-7 data readout; highlights cell therapy opportunity
• Other milestones: HIV (lenacapavir), HDV (bulevirtide), Arcus collab. (domvanalimab)
• Increasingly diversifying business across indications and therapies
• Growing revenue contributions from oncology (Cell Therapy and Trodelvy)
• Reinforcing long-term competitive positioning in virology with long-acting HIV filing

4

Select 2021 Oncology and Virology Milestones

1H21	Program
YESCARTA®
	TRODELVY
	DOMVANALIMAB1
	LENACAPAVIR
	HEPCLUDEX®
2H21	TRODELVY
MAGROLIMAB

TECARTUS® LENACAPAVIR LENACAPAVIR LENACAPAVIR + ISLATRAVIR HEPCLUDEX

Trial	Anticipated Milestone
ASCENT	Full approval for 2L+ mTNBC
TROPHY U-01	sBLA Accelerated Approval in 2L+ mUC
ZUMA-7	Phase 3 data readout for 2L LBCL (potential submissions in 2H21)
ARC-7	Phase 2 NSCLC interim data readout
PURPOSE-2	Phase 3 initiation in PrEP2
MYR301	Phase 3 data readout in 1H21
TROPiCS-02	Phase 3 HR+/HER2- PFS readout
	Phase 1b data readout, potential BLA submission for Accelerated
	Approval in MDS
ZUMA-3	FDA approval for adult ALL
CALIBRATE	Phase 2 data readout for HIV treatment naïve population3
PURPOSE-1	Phase 3 initiation in PrEP4
	Phase 2 initiation for long-acting oral HIV treatment
	Potential BLA submission in HDV

5	1 Potential opt-in Arcus program. 2 For cisgender men, transgender women and men, and gender non-binary people who have sex with men. 3 CALIBRATE is a	Completed	On track
	study of HIV in treatment naïve population to support a virologically suppressed indication. 4 For adolescent girls and young women.